The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility

被引:46
作者
MacGowan, AP [1 ]
Wootton, M
Holt, HA
机构
[1] Southmead Hlth Serv NHS Trust, Bristol Ctr Antimicrobiol Res & Evaluat, Bristol BS10 5NB, Avon, England
[2] Univ Bristol, Southmead Hosp, Dept Med Microbiol, Bristol BS10 5NB, Avon, England
关键词
D O I
10.1093/jac/43.3.345
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Ciprofloxacin has a four-fold greater in-vitro activity than levofloxacin against Pseudomonas aeruginosa, but levofloxacin has a four-fold higher area under the serum concentration-time curve (AUC) for an equivalent dose. It has been proposed that the AUC/MIC ratio is a general predictor of antibacterial efficacy for quinolones. Using an in-vitro kill curve technique, performed in quadruplicate, with nine antibiotic concentrations and three strains of P. aeruginosa with varying quinolone susceptibility, we constructed sigmoidal dose-response curves for AUC(0-6.5)/MIC and area under the bacterial kill curve (AUBKC) or AUC(0-24)/MIC and log change in viable count at 24 h (Delta 24). For levofloxacin the log AUC(0-6.5)/MIC ratio to produce 50% of the maximal effect was 0.74 +/- 0.13 (r(2) = 0.9435) for levofloxacin and 0.82 +/- 0.06 (r(2) = 0.7935) for ciprofloxacin. The log AUC(0-24)/MIC ratio to produce 50% maximal effect was 1.58 +/- 0.13 (r(2) = 0.7788) for levofloxacin and 1.37 +/- 0.12 (r(2) = 0.7207) for ciprofloxacin. An AUC(0-24)/MIC ratio of 125 produced 85.4% of the maximal response with levofloxacin and 81.5% with ciprofloxacin. These data suggest that levofloxacin and ciprofloxacin have equivalent activity against P. aeruginosa at equivalent AUC/MIC ratios.
引用
收藏
页码:345 / 349
页数:5
相关论文
共 20 条
[1]  
BERGAN T, 1987, AM J MED, V82, P97
[2]   COMPARATIVE-STUDY WITH ENOXACIN AND NETILMICIN IN A PHARMACODYNAMIC MODEL TO DETERMINE IMPORTANCE OF RATIO OF ANTIBIOTIC PEAK CONCENTRATION TO MIC FOR BACTERICIDAL ACTIVITY AND EMERGENCE OF RESISTANCE [J].
BLASER, J ;
STONE, BB ;
GRONER, MC ;
ZINNER, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (07) :1054-1060
[3]  
BOWKER KE, 1996, 36 INT C ANT AG CHEM, P9
[4]  
BOWKER KE, 1997, 37 INT C ANT AG CHEM
[5]   PHARMACODYNAMICS OF A FLUOROQUINOLONE ANTIMICROBIAL AGENT IN A NEUTROPENIC RAT MODEL OF PSEUDOMONAS SEPSIS [J].
DRUSANO, GL ;
JOHNSON, DE ;
ROSEN, M ;
STANDIFORD, HC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (03) :483-490
[6]   Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: Action of ciprofloxacin against Escherichia coli in an in vitro dynamic model [J].
Firsov, AA ;
Vostrov, SN ;
Shevchenko, AA ;
Cornaglia, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1281-1287
[7]   The clinical pharmacokinetics of levofloxacin [J].
Fish, DN ;
Chow, AT .
CLINICAL PHARMACOKINETICS, 1997, 32 (02) :101-119
[8]   PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS [J].
FORREST, A ;
NIX, DE ;
BALLOW, CH ;
GOSS, TF ;
BIRMINGHAM, MC ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1073-1081
[9]  
FORREST A, 1993, 33 INT C ANT AG CHEM, P134
[10]  
GEORGE J, 1997, CLIN MICROBIOLOGY S2, V3, P293